Anika Therapeutics (ANIK) Tops Q1 EPS by 45c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.40 +4.88%
EPS Growth %: +950.0%
Financial Fact:
Total revenue: 25.79M
Today's EPS Names:
KTB, CABO, FDUS, More
EPS Growth %: +950.0%
Financial Fact:
Total revenue: 25.79M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.27, $0.45 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $28.11 million.
GUIDANCE:
Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $117.2 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Timken (TKR) PT Lowered to $126 at Goldman Sachs
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
